No description available.

No description available.

Thesis (Ph. D.)--Washington State University, December 2009. / Title from PDF title page (viewed on Dec. 9, 2009). "College of Education." Includes bibliographical references (p. 84-88).

No description available.

Magister Chirurgiae Dentium - MChD / Introduction: Maxillofacial and oral surgeons often encounter challenges when choos-ing an appropriate surgical access for patients who sustained periorbital and orbital trauma. There are various surgical approaches/incisions (transcutaneous and transcon-junctival) used to access the periorbital skeletal framework. However, there is no consen-sus in the literature regarding the aesthetical outcome of these approaches/incisions. Complications of the lower lid such as entropion, ectropion, retraction of lower lid, scar-ring, oedema of lid, canthal mal-position and chemosis are associated with these ap-proaches. Surgeons are posed with these challenges and aim for best aesthetic outcomes and low post-operative complications. Aim: The aim of this study was to compare aesthetic outcome of the transcutaneous ap-proach (subtarsal) to that of the transconjunctival approach when managing orbital trauma. Objectives: The objectives were to compare the aesthetic outcomes between the trans-conjunctival and transcutaneous (subtarsal) approach; to assess unwanted clinical out-comes, such as scaring, lid malposition (ectropion, entropion, scleral show), lid oedema, chemosis, haematoma, ecchymosis, wound dehiscence, infection and canthal malposition for the two approaches. Methodology: Twenty-two patients were enrolled in this study, 11 of which underwent “transconjunctival incision”, and 11 underwent "subtarsal incision". A high quality dig-ital photograph of each patient’s face was taken at specified time periods up to nine months after surgery. Ten Maxillofacial and Plastic surgeons were instructed to rank or-der the 22 photographs applying Q-sort scaling. Results: Eleven patients underwent the transconjunctival (retroseptal) incision. Ten of which had pure blowout fractures and one had a zygomatic complex fracture. Of the 11, seven were black Africans, two were Caucasians and two mixed race. There were four males and seven females in the transconjunctival incision group. The remainder of the 22 underwent the transcutaneous (subtarsal) incision. Six of the 11 were black Africans and five mixed race. There were nine males and two females in the tranconjunctival group. In this group, two patients had pure blowout fractures and nine had zygomatic complex fractures. Scars were visible in the subtarsal group after six months in seven out of the 11 cases (63.6%), but all the scars were rated as mild on the modified Vancouver Scar Scale. Scle-ral show was noted after six months in four of the 11 cases with the subtarsal approach and in two of the 11 cases with the transconjunctival approach. Only one case of ectropion was seen with both approaches and only one case of entropion was noted in the transcon-junctival group. According to the findings of the study, both approaches were found to have good aesthetic outcomes. Results from the expert rating showed a high-quality rank of 96.8% for the transconjunctival incision versus 90.5% for the subtarsal incision. Conclusion: Both approaches demonstrated good aesthetic results. The transconjunctival incision was associated with scleral show and entropion, while the subtarsal incision was more associated with scar formation. However, when performed meticulously, both inci-sions can provide aesthetically pleasing results.

Thesis (M.S.)--University of Michigan, 1981.

Thesis (M.S.)--University of Michigan, 1981.

M.Tech. (Homoeopathy) / Neck pain is a common condition usually experienced due to mechanical or degenerative problems (Colledge et al., 2010). The onset of neck pain may be acute and associated with asymmetrical restriction of neck movements and a history of awkward posture or sudden onset. Acute neck pain is an aching pain in the cervical paraspinal muscles and ligaments. It is associated with muscle spasm, stiffness and tightness in the upper back and shoulders that lasts up to six weeks. Headaches may be present (Bickley & Szilagyi, 2009). Causes of neck pain can be mechanical, inflammatory, metabolic, neoplastic, due to referred pain or other underlying aetiologies (Colledge et al., 2010). The most common treatments for neck pain are nonsteroidal anti-inflammatory drugs, physiotherapy, chiropractic adjustment or therapeutic massage (Taylor, 2010). The NeuroTrac® MultiTENS device provides a non-invasive, drug-free method of controlling acute pain by transmitting mild electrical impulses via surface electrodes through the skin (Verity Medical Ltd., 2013). There have been many studies done on Transcutaneous Electrical Nerve Stimulation (TENS) devices, but little on its immediate effect on acute neck pain. The aim of this study was to determine the immediate effect of the NeuroTrac® MultiTENS device on acute neck pain, using the Neck Pain Disability Index, Visual Analogue Scale and the Cervical Range of Motion (CROM). This study was an unblinded, single-group experimental design (Brink, 2010). The study took place at the University of Johannesburg Campus Clinic. Recruitment took place by means of advertisements (Appendix H) placed at the University of Johannesburg campuses. Inclusion criteria consisted of males and females between the ages of eighteen to fifty years. Participants had to be suffering from aching pain in the cervical paraspinal muscles and ligaments with associated muscle spasm, stiffness and tightness in the upper back and shoulders that was present for more than one day and no longer than one week, with decreased range of motion on CROMs (Appendix G) and a minimum score of 10 on the Neck Pain Disability Index (Appendix D). Exclusion criteria consisted of participants suffering from severe headaches with meningeal signs associated nausea, blurred vision, photophobia and phonophobia or fever; a history of thrombus formation or transient ischaemic attack (Longmore et al., 2010); if they had a pacemaker or if they have had any head and neck surgery; if they suffered from cardiac arrhythmia or myocardial infarction; pregnancy or suspected pregnancy; if they had a general skin sensitivity or known allergy to adhesives or if they have had a recent chiropractic adjustment. A total of forty participants were selected. The participants acted as their own baseline control. The researcher was only required to see participants once for one forty minute session to determine the immediate vi effect of the NeuroTrac® MultiTENS device on acute neck pain. Participants were asked to fill in an Information (Appendix A) and Consent Form (Appendix B). Participants came in for an initial consult where a history was taken on the type of neck pain experienced and the cause of the pain experienced. Vital signs were recorded on a case taking form (Appendix C). Thereafter participants were asked to fill in the Vernon and Mior Neck Pain Disability Index (Appendix D) relating to the neck pain they experienced and to complete a Visual Analogue Scale to rate their neck pain (Appendix F). The CROM goniometer device was placed on the participant’s head to measure all cervical spine ranges of motion, to the limit of pain (Appendix G). All forty participants received treatment at a frequency of 90Hz with a 200μS pulse width with the electronic pads placed on the shoulders. NeuroTrac® MultiTENS device treatment was administered for forty minutes to the participants in a seated position. The treatment was administered by the researcher. Once the treatment ended, participants were asked to fill in an amended questionnaire (Appendix E) that assessed if they noticed a change in the neck pain they were experiencing, to complete the Visual Analogue Scale (Appendix F) and their vital signs were again recorded on a case taking form (Appendix C). The CROM goniometer device was again placed on the participant’s head to measure all cervical spine ranges of motion to assess if there was a change in the readings recorded (Appendix G). The data obtained was statistically analysed by the researcher with the aid of a statistician at Statkon. The Shapiro-Wilk test and the Wilcoxon Signed-Rank test (non-parametric test) were used (Van Staden, 2014) ...

INTRODUÇÂO: Fibromialgia é caracterizada como síndrome, a qual inclui dor muscular, fadiga e distúrbio do sono. Ansiedade e depressão estão freqüentemente associados, porém a causa é desconhecida. A intensidade da dor piora ao se deitar, durante a noite e no despertar. Normalmente a dor se difunde na região lombar e cervical. A TENS é um método não medicamentoso, estabelecido para controle da dor, o qual minimiza o consumo de analgésicos. OBJETIVOS: Este estudo visou avaliar a utilização de dispositivos de TENS simultâneos em pacientes portadores de Fibromialgia. MÉTODOS: Após aprovação do Comitê de Ètica em Pesquisa e consentimento, 39 pacientes portadores de Fibromialgia foram avaliados de forma prospectiva, aleatória e duplamente-encoberta. Avaliou-se a utilidade clínica de um novo, muito pequeno e leve dispositivo de a TENS (TANYX). Dois dispositivos de TENS, foram aplicados de forma simultânea em cada paciente: 1) na região lombar (perpendicular à coluna sobre L5), e 2) na região cervical (perpendicular à coluna, entre C7 e T1), durante 20-min, a cada 12 horas, durante 7 dias consecutivos (antes de se deitar, à noite, e antes de se levantar, pela manhã). Os pacientes foram divididos em 3 grupos (n=13). O grupo placebo (GP) utilizou adesivos que não transmitiam estímulo elétrico, semelhantes aos originais. O grupo de únicoTENS (TENS-1) (n=13), utilizou um adesivo de TENS ativo na área mais dolorida (cervical ou lombar) e placebo na área menos doloroa. O terceiro grupo (TENS-2) utilizou dois adesivos ativos de TENS nas áreas cervical e lombar, simultaneamente. Para controlar a dor, diclofenaco (50mg) foi utilizado como analgésico de resgate, até três vezes ao dia. Foram avaliados a intensidade da dor através da escala numérica visual (ENV 0-10 cm), consumo de analgésicos de resgate, qualidade do sono e fadiga. RESULTADOS: Os pacientes foram demograficamente semelhantes. 36 pacientes completaram o estudo. Três pacientes do grupo placebo desistiram no 4o dia de ausência de alívio da dor. A avaliação entre cada grupo antes e após o tratamento revelou que pacientes do grupo placebo não apresentaram alívio da dor (ENV 8 cm, p>0,05), da fatiga, ou melhora do padrão de sono, enquanto o grupo TENS-1 apresentou diminuição de 2,5 cm na ENV para dor (ENV anterior 8,5 cm e após 6 cm) (p<0,05). Finalmente, o grupo TENS-2 referiu redução de 4 cm na intensidade da dor (ENV anterior ao tratamento 8,5 cm e 4,3 cm após tratamento) (p<0,02). O consumo de analgésicos diários foi menor para TENS-1 (p<0,05) e TENS-2 (p<0,02). A comparação entre os 3 grupos revelou que a analgesia, qualidade de sono e melhora da fadiga foi: grupo TENS-2 > TENS-1 > GP (p<0,05). Os participantes consideraram os aparelhos ativos úteis. Não foram observados efeitos adversos. CONCLUSÕES: enquanto a aplicação de um dispositivo de TENS na área dolorida, lombar ou cervical, amenizou a dor em pacientes portadores de fibromialgia, a fadiga e a qualidade do sono foram minimizadas apenas quando dois dispositivos foram utilizados, demonstrando que este novo dispositivo pode ser adjuvante para dor da fibromialgia. / BACKGROUND: Fibromyalgia is characterized by a range of symptoms that include muscle pain, fatigue and sleep disorders. Anxiety and depression are often also present, and the cause is unknown. Worst pain is normally felt during bedtime, at night and before waking up in the morning, and pain is normally widespread at the low back and cervical area. Transcutaneous electrical nerve stimulation (TENS) is an established method for pain relief, which does not involve the use of medication and can be advantageous, as adjuvant, for pain control. OBJECTIVES: The purpose of the study was to evaluate the effectiveness and safety of the use of two simultaneously new TENS devices for Fibromyalgia pain. METHODS: The local Ethics Committee approved the study, and informed consent was obtained. This prospective, double-blind randomized study evaluated the clinical utility of a new, very small and light, high frequency TENS device (TANYX) in 39 patients suffering from Fibromyalgia. Two TENS device were applied simultaneously in each patient: 1) at the lower back (perpendicular to the vertebrae canal, at the level of the 5th lumbar vertebrae), and 2) centrally above and below the space between the C7 and T1 spinous processes, perpendicular to the spine. The two devices were applied during 20-min at 12-hour interval during 7 consecutive days (Before bed-time and just after waking up in the morning). Patients were randomly divided into three groups (n=13): For the placebo group (PG), the two devices did not transmitted electrical stimulus, although they were externally similar to the active ones. The single-TENS group (STG) had applied one active TENS device at the worst area of pain (low back or cervical), and the placebo device at the less painful area. The third group double-TENS group (DTG) applied both active TENS devices at the low back and cervical areas. Diclofenac (50 mg) up to three times daily was used as rescue analgesic if necessary for pain control. The efficacy measures were pain relief evaluated on a visual analogue scale (VAS 0-10 cm),, reduction in use of daily analgesic tablets, quality of sleep, and fatigue. MAIN RESULTS: Patients were demographically similar. 36 patients completed the study. Three patients from the PG give up the study on the fourth day for absence of any pain relief. The evaluation within groups revealed that patients from DPG refereed no pain relief when compared to their previous VAS pain score (8-cm, p>0.05), while patients from the STG refereed improvement of 2.5 cm in the pain VAS (previous 8.5 cm compared to 6-cm after treatment) (p<0.05); and the DPG refereed daily maintained reduction of 4 cm in the VAS-pain (previous 8.5-cm to 4.3-cm) (p<0.02). Concurrent daily consumption of analgesic tablets was reduced in both STG (p<0.05) and DTG (p<0.02). Comparison among groups revealed that analgesia, as well as quality of sleep and disposition was: DTG > STG > PG (p<0.05). Participants subjectively found the active device useful. No adverse effects were observed. CONCLUSIONS: while the application of one active TENS device at either the lower back or cervical area improved pain relief in patients suffering from Fibromyalgia pain, the pain and fatigue were further improved when two actives devices were simultaneously applied, reflecting this new device an useful adjuvant for Fibromyalgia pain.

INTRODUÇÂO: Fibromialgia é caracterizada como síndrome, a qual inclui dor muscular, fadiga e distúrbio do sono. Ansiedade e depressão estão freqüentemente associados, porém a causa é desconhecida. A intensidade da dor piora ao se deitar, durante a noite e no despertar. Normalmente a dor se difunde na região lombar e cervical. A TENS é um método não medicamentoso, estabelecido para controle da dor, o qual minimiza o consumo de analgésicos. OBJETIVOS: Este estudo visou avaliar a utilização de dispositivos de TENS simultâneos em pacientes portadores de Fibromialgia. MÉTODOS: Após aprovação do Comitê de Ètica em Pesquisa e consentimento, 39 pacientes portadores de Fibromialgia foram avaliados de forma prospectiva, aleatória e duplamente-encoberta. Avaliou-se a utilidade clínica de um novo, muito pequeno e leve dispositivo de a TENS (TANYX). Dois dispositivos de TENS, foram aplicados de forma simultânea em cada paciente: 1) na região lombar (perpendicular à coluna sobre L5), e 2) na região cervical (perpendicular à coluna, entre C7 e T1), durante 20-min, a cada 12 horas, durante 7 dias consecutivos (antes de se deitar, à noite, e antes de se levantar, pela manhã). Os pacientes foram divididos em 3 grupos (n=13). O grupo placebo (GP) utilizou adesivos que não transmitiam estímulo elétrico, semelhantes aos originais. O grupo de únicoTENS (TENS-1) (n=13), utilizou um adesivo de TENS ativo na área mais dolorida (cervical ou lombar) e placebo na área menos doloroa. O terceiro grupo (TENS-2) utilizou dois adesivos ativos de TENS nas áreas cervical e lombar, simultaneamente. Para controlar a dor, diclofenaco (50mg) foi utilizado como analgésico de resgate, até três vezes ao dia. Foram avaliados a intensidade da dor através da escala numérica visual (ENV 0-10 cm), consumo de analgésicos de resgate, qualidade do sono e fadiga. RESULTADOS: Os pacientes foram demograficamente semelhantes. 36 pacientes completaram o estudo. Três pacientes do grupo placebo desistiram no 4o dia de ausência de alívio da dor. A avaliação entre cada grupo antes e após o tratamento revelou que pacientes do grupo placebo não apresentaram alívio da dor (ENV 8 cm, p>0,05), da fatiga, ou melhora do padrão de sono, enquanto o grupo TENS-1 apresentou diminuição de 2,5 cm na ENV para dor (ENV anterior 8,5 cm e após 6 cm) (p<0,05). Finalmente, o grupo TENS-2 referiu redução de 4 cm na intensidade da dor (ENV anterior ao tratamento 8,5 cm e 4,3 cm após tratamento) (p<0,02). O consumo de analgésicos diários foi menor para TENS-1 (p<0,05) e TENS-2 (p<0,02). A comparação entre os 3 grupos revelou que a analgesia, qualidade de sono e melhora da fadiga foi: grupo TENS-2 > TENS-1 > GP (p<0,05). Os participantes consideraram os aparelhos ativos úteis. Não foram observados efeitos adversos. CONCLUSÕES: enquanto a aplicação de um dispositivo de TENS na área dolorida, lombar ou cervical, amenizou a dor em pacientes portadores de fibromialgia, a fadiga e a qualidade do sono foram minimizadas apenas quando dois dispositivos foram utilizados, demonstrando que este novo dispositivo pode ser adjuvante para dor da fibromialgia. / BACKGROUND: Fibromyalgia is characterized by a range of symptoms that include muscle pain, fatigue and sleep disorders. Anxiety and depression are often also present, and the cause is unknown. Worst pain is normally felt during bedtime, at night and before waking up in the morning, and pain is normally widespread at the low back and cervical area. Transcutaneous electrical nerve stimulation (TENS) is an established method for pain relief, which does not involve the use of medication and can be advantageous, as adjuvant, for pain control. OBJECTIVES: The purpose of the study was to evaluate the effectiveness and safety of the use of two simultaneously new TENS devices for Fibromyalgia pain. METHODS: The local Ethics Committee approved the study, and informed consent was obtained. This prospective, double-blind randomized study evaluated the clinical utility of a new, very small and light, high frequency TENS device (TANYX) in 39 patients suffering from Fibromyalgia. Two TENS device were applied simultaneously in each patient: 1) at the lower back (perpendicular to the vertebrae canal, at the level of the 5th lumbar vertebrae), and 2) centrally above and below the space between the C7 and T1 spinous processes, perpendicular to the spine. The two devices were applied during 20-min at 12-hour interval during 7 consecutive days (Before bed-time and just after waking up in the morning). Patients were randomly divided into three groups (n=13): For the placebo group (PG), the two devices did not transmitted electrical stimulus, although they were externally similar to the active ones. The single-TENS group (STG) had applied one active TENS device at the worst area of pain (low back or cervical), and the placebo device at the less painful area. The third group double-TENS group (DTG) applied both active TENS devices at the low back and cervical areas. Diclofenac (50 mg) up to three times daily was used as rescue analgesic if necessary for pain control. The efficacy measures were pain relief evaluated on a visual analogue scale (VAS 0-10 cm),, reduction in use of daily analgesic tablets, quality of sleep, and fatigue. MAIN RESULTS: Patients were demographically similar. 36 patients completed the study. Three patients from the PG give up the study on the fourth day for absence of any pain relief. The evaluation within groups revealed that patients from DPG refereed no pain relief when compared to their previous VAS pain score (8-cm, p>0.05), while patients from the STG refereed improvement of 2.5 cm in the pain VAS (previous 8.5 cm compared to 6-cm after treatment) (p<0.05); and the DPG refereed daily maintained reduction of 4 cm in the VAS-pain (previous 8.5-cm to 4.3-cm) (p<0.02). Concurrent daily consumption of analgesic tablets was reduced in both STG (p<0.05) and DTG (p<0.02). Comparison among groups revealed that analgesia, as well as quality of sleep and disposition was: DTG > STG > PG (p<0.05). Participants subjectively found the active device useful. No adverse effects were observed. CONCLUSIONS: while the application of one active TENS device at either the lower back or cervical area improved pain relief in patients suffering from Fibromyalgia pain, the pain and fatigue were further improved when two actives devices were simultaneously applied, reflecting this new device an useful adjuvant for Fibromyalgia pain.